Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong Zheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Jianlin Jiao

    Science and Technology Achievement Incubation Center Kunming Medical University Kunming Yunnan P. R. China

    4 shared publications
  • Yi Yang

    Deparment of Laboratory Animal Science Kunming Medical University Kunming Yunnan P. R. China

    4 shared publications
  • Jiangli Lu

    Deparment of Laboratory Animal Science Kunming Medical University Kunming Yunnan P. R. China

    3 shared publications
  • Limei Wang

    Deparment of Laboratory Animal Science Kunming Medical University Kunming Yunnan P. R. China

    3 shared publications
  • Peijin Wang

    Deparment of Laboratory Animal Science Kunming Medical University Kunming Yunnan P. R. China

    3 shared publications
  • Rong Li

    Deparment of Laboratory Animal Science Kunming Medical University Kunming Yunnan P. R. China

    3 shared publications

Latest Publications

  • Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation

    by Rong Li, Jiangli Lu, Peijin Wang, Yulan Zhao, Yi Yang, Jianlin Jiao, Zhongyi Qian, Limei Wang, Hong Zheng

    Osteoking (OK) exerts bone formation‐promoting effects on menopausal osteoporosis and osteoporotic fractures. However, it remains to be determined whether OK ameliorates type 2 diabetic osteoporosis (T2DOP) via PI3K/AKT/GSK‐3β pathway activation. Thus, the T2DOP animal model was established in db/db mice in this study. Microcomputed tomography (micro‐CT) analysis revealed that OK significantly increased bone strength, improved bone metabolism, and promoted bone formation. GS and p‐GSK‐3β expression levels were increased in OK group as compared with db/db group by western blot analysis. IL‐6, IL‐17A, IFN‐γ, TNF‐α, and IL‐1β were lower levels in the OK group compared to the db/db group, nevertheless, the IL‐10 level was significantly higher. Furthermore, an in vitro cells model was constructed by stimulating with high glucose (HG, 30 mM). ALP protein was significantly elevated in the OK treatment group. Administration of OK at 0.288 mg/mL significantly increased p‐AKT/AKT expression, while, combined with LY294002, an inhibitor of PI3K, OK significantly reduced the expression levels of p‐PI3K/PI3K, p‐AKT/AKT, and p‐GSK‐3β/GSK‐3β. In conclusion, this study reveals OK exhibits efficacy against T2DOP in db/db mice by promoting osteogenesis of preosteoblast MC3T3‐E1 cells through PI3K/AKT/GSK‐3β pathway regulation.


  • Osteoking prevents bone loss and enhances osteoblastic bone formation by modulating the AGEs/IGF‐1/β‐catenin/OPG pathway in type 2 diabetic db/db mice

    by Yi Yang, Rong Li, Peijin Wang, Yulan Zhao, Jintao Li, Jianlin Jiao, Hong Zheng

    Type 2 diabetic osteoporosis (T2DOP) is a skeletal metabolic syndrome characterized by impaired bone remodeling due to type 2 diabetes mellitus, and there are drawbacks in the present treatment. Osteoking (OK) is widely used for treating fractures and femoral head necrosis. However, OK is seldom reported in the field of T2DOP, and its role and mechanism of action need to be elucidated. Consequently, this study investigated whether OK improves bone remodeling and the mechanisms of diabetes‐induced injury. We used db/db mice as a T2DOP model and stimulated MC3T3‐E1 cells (osteoblast cell line) with high glucose (HG, 50 mM) and advanced glycation end products (AGEs, 100 µg/mL), respectively. The effect of OK on T2DOP was assessed using a combined 3‐point mechanical bending test, hematoxylin and eosin staining, and enzyme‐linked immunosorbent assay. The effect of OK on enhancing MC3T3‐E1 cell differentiation and mineralization under HG and AGEs conditions was assessed by an alkaline phosphatase activity assay and alizarin red S staining. The AGEs/insulin‐like growth factor‐1(IGF‐1)/β‐catenin/osteoprotegerin (OPG) pathway‐associated protein levels were assayed by western blot analysis and immunohistochemical staining. We found that OK reduced hyperglycemia, attenuated bone damage, repaired bone remodeling, increased tibial and femoral IGF‐1, β‐catenin, and OPG expression, and decreased receptor activator of nuclear kappa B ligand and receptor activator of nuclear kappa B expression in db/db mice. Moreover, OK promoted the differentiation and mineralization of MC3T3‐E1 cells under HG and AGEs conditions, respectively, and regulated the levels of AGEs/IGF‐1/β‐catenin/OPG pathway‐associated proteins. In conclusion, our results suggest that OK may lower blood glucose, alleviate bone damage, and attenuate T2DOP, in part through activation of the AGEs/IGF‐1/β‐catenin/OPG pathway.


  • Open Access

    Osteoking ameliorates type 2 diabetes osteoporosis by promoting osteoblasts proliferation via PI3K/AKT/GSK-3β pathway activation

    by Rong Li, Jiangli Lu, Peijin Wang, Yulan Zhao, Yi Yang, Jianlin Jiao, Zhongyi Qian, Limei Wang, Hong Zheng

    Osteoking (OK) is a Yi folk Chinese herb from the Yunnan province, which exerts bone formation-promoting effects on menopausal osteoporosis and osteoporotic fractures. However, it remains to be determined whether OK ameliorates type 2 diabetic osteoporosis (T2DOP). Thus, T2DOP animal model was established in db/db mice in this study. Micro-computed tomography (micro-CT) analysis revealed that OK significantly increased bone strength, improved bone metabolism, and promoted bone formation. GS and p-GSK-3β expression levels were increased in OK group as compared with db/db group by Western blot analysis. IL-6, IL-17A, IFN-γ, TNF-α, and IL-1β were lower levels in the OK group compared to the db/db group, nevertheless, the IL-10 level was significantly higher. Furthermore, an In vitro cells model was constructed by stimulating with high glucose (HG, 30 mM). ALP protein was significantly elevated in OK treatment group. Administration of OK at 1.44 mg/mL significantly increased p-AKT/AKT expression, while, combined with LY294002, an inhibitor of PI3K, OK significantly reduced the expression levels of p-PI3K/PI3K, p-AKT/AKT and p-GSK-3β/GSK-3β. In conclusion, to our knowledge, this study is the first to reveal OK exhibits efficacy against T2DOP in db/db mice by promoting osteogenesis of preosteoblast MC3T3-E1 cells through PI3K/AKT/GSK-3β pathway regulation.

  • Open Access

    Ginsenoside Rg1 improves cognitive capability and affects the microbiota of large intestine of tree shrew model for Alzheimer's disease

    by Yuqian Guo, Limei Wang, Jiangli Lu, Jianlin Jiao, Yi Yang, Hongbin Zhao, Zhang Liang, Hong Zheng

    Ginsenoside Rg1 (Rg1) is traditional Chinese medicine with neuroprotective activity. Previous studies have demonstrated that Rg1 improves Alzheimer's disease (AD) and alters gut microbiology, but its mechanism remains to be elucidated, and thus far, its use in the treatment of AD has not been satisfactory. The present study investigated the improvement effects of Rg1 and its association with the microbiota of the large intestine. Following treatment with Rg1 in AD tree shrews, the treatment group demonstrated significantly shorter escape latency and crossed a platform more frequently in a water maze test. Western blotting demonstrated that Rg1 inhibited the expression of β-secretase 1, while increasing microtubule-associated protein 2 and Fox-3 in the hippocampus. Immunohistochemical analysis revealed that Rg1 decreased the expression of amyloid β, tau phosphorylated at serine 404 and pro-apoptotic factor Bax, while increasing the expression of Bcl-2 in the hippocampus and cortex. High throughput sequencing of 16S rRNA demonstrated that Rg1 altered the microbiota abundance of the large intestine. In conclusion, Rg1 affected the expression of apoptosis proteins, possessed a neuroprotective effect and may have a close association with the microbiota of large intestine by significantly reducing the abundance of Bacteroidetes and increasing the energy requirement of tree shrews.